HOME >> MEDICINE >> NEWS
SARS vaccine development

While there have been only isolated cases of SARS since the 2003/2004 epidemic, it is likely that we will see future outbreaks. As a result, a number of laboratories are working on strategies for a SARS vaccine. One promising approach is being reported by Jan ter Meulen and colleagues.

The researchers developed a strategy called passive immunization, in which combinations of antibodies against the SARS virus are given to individuals at risk at the time of a possible new outbreak. Passive immunization strategies have been shown to curb outbreaks of hepatitis A virus and to prevent infection with varicella-zoster virus, and such antibody prophylaxis may be an effective means of controlling a future SARS outbreak.

To be effective, it is important that an antibody-based vaccine offers sufficient breadth of protection against all relevant strains of the SARS virus and prevents the selection of escape variants in the patient. In their study, the researchers present the characteristics of a combination of two human monoclonal antibodies that seem to have the desired characteristics in cell-culture experiments in the laboratory.


'"/>

Contact: Andrew Hyde
ahyde@plos.org
44-122-346-3330
Public Library of Science
3-Jul-2006


Page: 1

Related medicine news :

1. Traditional Chinese exercises may increase efficacy of flu vaccine
2. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
3. Study reveals gaps in vaccine financing for underinsured children
4. Trials underway for essential new TB vaccine
5. Hib vaccine: A critical ally in Asias effort to reduce child deaths
6. Progress toward an antitumor vaccine
7. Chemotherapy may enhance the effectiveness of brain tumor vaccines
8. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
9. International studies show high efficacy for HPV vaccine
10. Vaxfectin-formulated measles DNA vaccine elicits long-term protection in nonhuman primates
11. Papillomavirus vaccine could substantially reduce cervical cancer incidence

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors is expanding ... extensive knowledge of appraisals, property values, ad valorem taxation, and government policy to ... for more than 40 years. , “Ruel is a great addition to the ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a ... Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip ... in association with efforts by the American College of Surgeons, U.S. Department of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical ... begin serving as new board chair for Orange County health care system CalOptima ... remainder of soon-to-be former chair Mark Refowitz’s term, which runs through June 30 ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing effort ... has recently developed and published an informational resource that addresses frequently asked questions. ... common inquiries the site’s team of third party administrator (TPA) contributors regularly receives ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
(Date:3/27/2017)... , March 27, 2017 The National ... health and data analytics company, signed a Memorandum ... improving healthcare delivery in the region. ... Global Health Research and Technology (BIGHEART) at NUS ... several topics related to healthcare IT and medical ...
(Date:3/27/2017)... 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage ... early toxicology and efficacy studies. The company is harnessing ... specific protein, MAGE A, in an effort to find ... After 4 weeks of treatment in transgenic ... little toxicity in a full toxicology report of various ...
Breaking Medicine Technology:
Cached News: